MET and cancer: As a whole, our results point to KRAS being the crucial signaling effector that is responsible for facilitating MET-driven growth in METΔexon14-addicted cells, while also playing a role in maintaining growth and tumourigenesis in MET WT-addicted cancer cells as well.